Enlivex Therapeutics

NASDAQ ENLV
$1.07 0.0100 0.94%
Today share price
Israel
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 15 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
21.24M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
19.43M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.11
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
21.90M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-8.55 %

Upcoming events Enlivex Therapeutics

All events
No upcoming events scheduled

Stock chart Enlivex Therapeutics

Stock analysis Enlivex Therapeutics

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.48 15.73
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
1.02 2.84
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-1.40 12.37
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.13 -
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-69.45 6.05

Price change Enlivex Therapeutics per year

0.84$ 1.82$
Min Max

Summary analysis Enlivex Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Enlivex Therapeutics

Revenue and net income Enlivex Therapeutics

All parameters

About company Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.
Address:
14 Einstein Street, Ness Ziona, Israel, 7403618
Company name: Enlivex Therapeutics
Issuer ticker: ENLV
ISIN: IL0011319527
Country: Israel
Exchange: NASDAQ
Currency: $
IPO date: 1995-12-12
Site: https://www.enlivex.com